What were the key financial results for ALS Limited (ASX:ALQ) in FY26?

ALS Limited delivered strong full-year results, highlighted by a 10.7% increase in revenue to $3.32 billion and a 25.8% surge in underlying net profit after tax (NPAT) to $381.2 million.

Which business divisions drove the revenue growth for ALS Limited (ASX:ALQ)?

The top-line expansion was spearheaded by strong organic growth within the company's commodities division alongside a solid performance in its life sciences unit.

Why did the underlying EBIT margin improve for ALS Limited (ASX:ALQ)?

How did the mid-2025 equity raising impact ALS Limited’s (ASX:ALQ) profitability?

The mid-2025 equity raising helped lower interest costs for the company over the financial year. This reduction in financing costs, combined with strong operational results, acted as a key catalyst for the 25.8% increase in underlying net profit after tax (NPAT), which reached $381.2 million.

What is the dividend payout for ALS Limited (ASX:ALQ) shareholders following these results?

The board declared a final dividend of 23.1 cents per share, representing a 57% payout ratio. This brings the total full-year dividend for ALS Limited shareholders to 42.5 cents per share. The payout is backed by a robust balance sheet and strong cash generation over the period.

How strong is the balance sheet and cash flow for ALS Limited (ASX:ALQ)?

ALS Limited maintained a highly robust balance sheet, generating $674.1 million in free cash flow for the full year. Capital management initiatives and strong cash generation allowed the company to reduce its leverage ratio to 1.5x, giving it increased financial flexibility.

Image for illustrative purposes only. Not a real photo.

ALS delivers record FY26 results following commodities growth

Written by Isaac FrancisPublished May 17, 2026, 11:59 PMLast Updated Jul 3, 2026, 11:15 AM

Testing and certification global leader ALS (ASX:ALQ) has delivered its financial result for the full year ended March 31, driven by robust performance across its core divisions.

The company reported a 10.7% increase in revenue to $3.32 billion, up from $3 billion in FY25.

The top-line expansion was spearheaded by strong organic growth within its commodities division and a solid performance in life sciences.

Underlying EBIT rose by 19.3% to $599 million, with the underlying EBIT margin improving by 129 basis points to 18%.

The margin improvement reflects strong operational leverage and positive pricing evolution in the commodities sector during the second half of the year, which successfully offset softer trading conditions and project delays in the Americas.

Driven by strong operational results and lower interest costs following a mid-2025 equity raising, underlying net profit after tax climbed by 25.8% to $381.2 million.

Statutory NPAT also experienced growth, increasing by 24.4% to $318.7 million.

ALS maintained a robust balance sheet, generating $674.1 million in free cash flow while reducing its leverage ratio to 1.5x.

The board declared a final dividend of 23.1 cents per share (representing a 57% payout ratio), bringing the total full-year dividend to 42.5 cents per share.

ALS delivers record FY26 results following commodities growth

Frequently asked questions

Assets related to this article